Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial
Neoadjuvante anthrazyklinbasierte (5-FEC) oder anthrazyklinfreie (Docetaxel/Carboplatin) Chemotherapie plus Trastuzumab und Pertuzumab bei HER2-positivem Brustkrebs entsprechend TOP2A: multizentrische, offene, nicht randomisierte Phase-II-Studie
Breast Cancer Research and Treatment · 2024-06 · 205 (2) · 267-279
DOI: 10.1007/s10549-024-07285-y ↗Auf einen Blick
Bei HER2-positivem Brustkrebs waren die pCR-Raten unter zwei neoadjuvanten Regimen mit Trastuzumab und Pertuzumab in beiden TOP2A-Gruppen hoch und ähnlich.
Fragestellung
Unterscheidet sich die Wirksamkeit einer anthrazyklinbasierten gegenüber einer anthrazyklinfreien neoadjuvanten Chemotherapie plus Trastuzumab/Pertuzumab je nach TOP2A-Status bei HER2-positivem Brustkrebs?
Methode
Offene, multizentrische Phase-II-Studie bei operablem HER2-positivem Brustkrebs. TOP2A+-Patient:innen erhielten 3 Zyklen FEC100, dann 3 Zyklen Trastuzumab, Pertuzumab und Docetaxel; TOP2A- erhielten 6 Zyklen Docetaxel/Carboplatin plus Trastuzumab/Pertuzumab.
Ergebnisse
74 Patient:innen: 41 TOP2A+ und 33 TOP2A-. pCR (Chevallier): 74,4 % (95 %-KI 58,9–85,4) vs. 71,9 % (95 %-KI 54,6–84,4). pCR (Sataloff): 70,6 % vs. 61,5 %; 5-Jahres-PFS 82,4 % vs. 100 %; OS 90 % vs. 100 %.
Schlussfolgerung der Autor:innen
Die Autor:innen berichten hohe pCR-Raten mit Trastuzumab und Pertuzumab plus Chemotherapie. Die Raten waren in beiden TOP2A-Gruppen ähnlich; die Rolle einer neoadjuvanten anthrazyklinhaltigen Chemotherapie bleibt fraglich.
Kernaussagen
- Hohe pCR-Raten in beiden TOP2A-Gruppen
- Chevallier-pCR: 74,4 % vs. 71,9 %
- Die Rolle anthrazyklinhaltiger Neoadjuvanz bleibt fraglich
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 07.03.2024. Verfasst von Angeline Ginzac und 20 weiteren Autor:innen. Beteiligte Einrichtung: INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, F- 63000, France. angeline.gi…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Trastuzumab, Breast Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche France, Unicancer.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Previous studies have reported the benefit of dual HER2-targeting combined to neoadjuvant chemotherapy in HER2-amplified breast cancer (HER2 + BC). Moreover, besides the cardiac toxicity following their association to Trastuzumab, anthracyclines chemotherapy may not profit all patients. The NeoTOP study was designed to evaluate the complementary action of Trastuzumab and Pertuzumab, and the relevance of an anthracycline-based regimen according to TOP2A amplification status.
Methods
Open-label, multicentre, phase II study. Eligible patients were aged ≥ 18 with untreated, operable, histologically confirmed HER2 + BC. After centralized review of TOP2A status, TOP2A-amplified (TOP2A+) patients received FEC100 for 3 cycles then 3 cycles of Trastuzumab (8 mg/kg then 6 mg/kg), Pertuzumab (840 mg/kg then 420 mg/kg), and Docetaxel (75mg/m 2 then 100mg/m 2 ). TOP2A-not amplified (TOP2A-) patients received 6 cycles of Docetaxel (75mg/m 2 ) and Carboplatin (target AUC 6 mg/ml/min) plus Trastuzumab and Pertuzumab. Primary endpoint was pathological Complete Response (pCR) using Chevallier’s classification. Secondary endpoints included pCR (Sataloff), Progression-Free Survival (PFS), Overall Survival (OS), and toxicity.
Results
Out of 74 patients, 41 and 33 were allocated to the TOP2A + and TOP2A- groups respectively. pCR rates (Chevallier) were 74.4% (95%CI: 58.9–85.4) vs. 71.9% (95%CI: 54.6–84.4) in the TOP2A + vs. TOP2A- groups. pCR rates (Sataloff), 5-year PFS and OS were 70.6% (95%CI: 53.8–83.2) vs. 61.5% (95%CI: 42.5–77.6), 82.4% (95%CI: 62.2–93.6) vs. 100% (95%CI: 74.1–100), and 90% (95%CI: 69.8–98.3) vs. 100% (95%CI: 74.1–100). Toxicity profile was consistent with previous reports.
Conclusion
Our results showed high pCR rates with Trastuzumab and Pertuzumab associated to chemotherapy. They were similar in TOP2A + and TOP2A- groups and the current role of neoadjuvant anthracycline-based chemotherapy remains questioned. Trial registration number NCT02339532 (registered on 14/12/14).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, F- 63000, France. angeline.ginzac@clermont.unicancer.fr.
- Centre d'Investigation Clinique UMR501, Clermont-Ferrand, F-63000, France. angeline.ginzac@clermont.unicancer.fr.
- Département de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, Clermont-Ferrand, F-63000, France. angeline.ginzac@clermont.unicancer.fr.
- INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne, Clermont-Ferrand, F- 63000, France.
- Centre d'Investigation Clinique UMR501, Clermont-Ferrand, F-63000, France.
- Département de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, Clermont-Ferrand, F-63000, France.
Förderung
- Roche France
- Unicancer
Zitieren
APA
Ginzac, A., Molnar, I., Durando, X., Motte Rouge, T., Petit, T., D'hondt, V., Campone, M., Bonichon-Lamichhane, N., Venat Bouvet, L., Levy, C., Augereau, P., Pistilli, B., Arsene, O., Jouannaud, C., Nguyen, S., Cayre, A., Tixier, L., Mahier Ait Oukhatar, C., Nabholtz, J. M., …, & Mouret-Reynier, M. A. (2024). Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast Cancer Research and Treatment, 205(2), 267-279. https://doi.org/10.1007/s10549-024-07285-y
Vancouver
Ginzac A, Molnar I, Durando X, Motte Rouge T, Petit T, D'hondt V, et al. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial. Breast Cancer Research and Treatment. 2024;205(2):267-279. doi:10.1007/s10549-024-07285-y
BibTeX
@article{Ginzac2024,
author = {Ginzac, Angeline and Molnar, Ioana and Durando, Xavier and Motte Rouge, Thibault De La and Petit, Thierry and D'hondt, Véronique and Campone, Mario and Bonichon-Lamichhane, Nathalie and Venat Bouvet, Laurence and Levy, Christelle and Augereau, Paule and Pistilli, Barbara and Arsene, Olivier and Jouannaud, Christelle and Nguyen, Suzanne and Cayre, Anne and Tixier, Lucie and Mahier Ait Oukhatar, Céline and Nabholtz, Jean-Marc and Penault-Llorca, Frédérique and Mouret-Reynier, Marie-Ange},
title = {Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial},
journal = {Breast Cancer Research and Treatment},
year = {2024},
volume = {205},
number = {2},
pages = {267--279},
doi = {10.1007/s10549-024-07285-y}
}
EUVIMED